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Background: Only few studies have assessed safety of in utero exposure to glatiramer acetate (GA). Following a
previous study assessing the safety of interferon beta (IFNB) pregnancy exposure in multiple sclerosis (MS), we
aimed to assess pregnancy and fetal outcomes after in utero exposure to GA, using the same dataset, with a
specific focus on the risk of spontaneous abortion.
Materials and methods: We recruited MS patients, prospectively followed-up in 21 Italian MS Centres, for whom a
pregnancy was recorded in the period 2002–2008. Patients were divided into 2 groups: drug-exposed pregnancies
(EP: suspension of the drug less than 4 weeks from conception); non-exposed pregnancies (NEP: suspension of the
drug at least 4 weeks from conception or never treated pregnancies). All the patients were administered a
structured interview which gathered detailed information on pregnancy course and outcomes, as well as on
possible confounders. Multivariate logistic and linear models were used for treatment comparisons.
Results: Data on 423 pregnancies were collected, 17 were classified as EP to GA, 88 as EP to IFNB, 318 as NEP.
Pregnancies resulted in 16 live births in the GA EP, 75 live births in the IFNB EP, 295 live births in the NEP. GA
exposure was not significantly associated with an increased risk of spontaneous abortion (OR = 0.44;95% CI
0.044-4.51;p = 0.49). Mean birth weight and length were not significantly different in pregnancies exposed to GA
than in non exposed pregnancies (p = 0.751). The frequency of preterm delivery, observed in 4 subjects exposed to
GA (25% of full term deliveries), was not significantly higher in pregnancies exposed to GA than in those non
exposed (p > 0.735). These findings were confirmed in the multivariate analysis. There were neither major
complications nor malformations after GA exposure.
Conclusions: Data in our cohort show that mother’s GA exposure is not associated with a higher frequency of
spontaneous abortion, neither other negative pregnancy and fetal outcomes. Our findings point to the safety of in
utero GA exposure and can support neurologists in the therapeutic counselling of MS women planning a
pregnancy.
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Since Multiple Sclerosis (MS) predominantly affects
women in childbearing phase of their lifes, the issue on
the tolerability and safety of disease-modifying therapy
(DMT) use in pregnant relapsing-remitting (RR) MS
patients has become increasingly important. This con-
cept is especially prominent in subjects with highly ac-
tive MS, in which the discontinuation of DMT in case of
pregnancy planning can expose the patients to the risk
of relapses. Over the past few years several studies have
suggested that exposure to Interferon-β (IFNB) therapies
during early pregnancy period is safe [1-4]. As for glatir-
amer acetate (GA) data in humans are rather limited. To
date, GA is classified by US FDA as a Category B drug
in relation to pregnancy, due to the absence of foetal risk
in animal studies [5]. However few studies suggested the
absence of adverse outcomes from GA exposure during
the early pregnancy [4,6-8]. In particular, a prospective
observational controlled cohort study on 31 pregnancies
exposed to GA found neither drug-specific adverse preg-
nancy outcomes nor birth defects compared to an MS
and non-MS control groups [6]. Moreover, two smaller
uncontrolled studies reported a preliminary experience
on continuous exposure of GA throughout the whole
course of pregnancy [9,10]. Neither drug-related obstetric/
neonatal complications nor malformations, were reported
in the pregnancies exposed to GA. The Authors also preli-
minarly suggested a protective role of continuos exposure
to GA during pregnancy against the risk of relapses in the
post-partum period.
In a previous multicentric, prospective study we col-
lected pregnancies followed-up in the main Italian MS
centers and addressed the issue of IFNB exposure. In the
same study we also gathered detailed information on
pregnancies exposed to GA [1]. The objective of this fur-
ther analysis was to determine the safety of in utero ex-
posure to GA in terms of pregnancy and foetal
outcomes as well as developmental abnormalities of the
babies after birth.
Methods
Recruitment of the patients begun in January 2002 and
ended in January 2008. In this period, all pregnancies
beginning in MS patients diagnosed according to Mac-
Donald’s criteria [11] and referred to the participating
centers were identified and tracked over the whole gesta-
tional period. The 21 participating sites represented the
main Italian MS Centers located throughout the entire
country. In each center the patients were regularly
followed-up every six months and in the case of relapse.
As described elsewhere [1], clinical and therapeutic data
were gathered by the neurologist using a standardized
information form. Within six months after the delivery,
the neurologist administered a semi-structured interviewto each patient dealing with pregnancy outcomes and
potential confounders. A specific section gathered infor-
mation on the pregnancies occurring during the study
period, focusing on in utero exposure to toxins, smoke,
alcohol, pharmacological therapies and timing of suspen-
sion in relationship with conception. Substance exposure
status was defined as “exposed “ (any exposure to any
substance in any trimester) and “never exposed” (no
substance exposure). Maternal smoking status was
defined as “never smoked” (no smoking in any trimester)
and “smoked” (smoking in any trimester). Alcohol ex-
posure status was defined as “exposed” (drinking more
than one unit per day), and “not-exposed” (drinking less
than one unit per day). Conception was determined as
14 days after the mother’s last menstrual period. Follow-
up data of the babies were also gathered and up-dated
every six months, following a specific section of the
questionnaire for the parents that investigated major de-
velopmental problems and malformations detected fol-
lowing birth. In case of problems, the baby’s clinical
charts were reviewed.
Patients were divided into two groups: those who had
discontinued the GA less than four weeks from concep-
tion (exposed), and those who had discontinued the drug
at least four weeks from the conception or who had
never been treated with DMTs (not-exposed). Data on
spontaneous abortion (occurring before 22 completed
weeks of gestation) and other outcomes (in particular,
weight and length of the baby, pre-term delivery,
cesarean delivery) were compared between the exposed
and not-exposed groups. The study was approved by the
ethic committee of the University of Florence and a writ-
ten consent was obtained from all patients.
Statistical analysis
Spontaneous abortion, birth-weight and birth-length,
pre-term delivery (<37 weeks) and caesarean delivery
were analyzed. Group comparisons was assessed with
Pearson’s χ [2] and Mann–Whitney U tests or analysis of
variance (ANOVA) with Bonferroni correction for mul-
tiple comparisons, when appropriate.
Multivariate logistic and linear models were used
for treatment comparisons, including as confounders
age at conception, educational level (as an indicator of
the socioeconomic status), disease duration, Expanded
Disability Status Scale [12], previous pregnancies and
abortions (yes vs no), smoking, alcohol and substance
exposure during pregnancy (yes vs no), gestational age,
caesarean delivery, gender of the baby. In the multivari-
ate analyses pregnancies exposed to IFNB or previously
treated with IFNB were excluded. Results are expressed
as odds ratios (ORs) or estimated means, and 95% confi-
dence intervals (CIs). P-values less than 0.05 were con-
sidered significant.
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Results
Study sample
A total of 423 pregnancies were tracked in 415 women.
The last pregnancy included took place on January 2008
(Figure. 1). The median follow-up period after the end of
pregnancy was 2.1 years. No woman was lost to the fol-
low-up. Forty (9.5%) women received glucocorticoid
treatment for relapses during pregnancy (58.8% during
the first, 32.4% during the second and 8.8% during the
third trimester). All glucocorticoid treatments during
pregnancy occurred in the non-exposed patients, al-
though the difference was not statistically significant
(p = 0.173). No patient received intravenous immuno-
globulins during the pregnancy.
Abortion
Full data on pregnancy and delivery were available for
423 pregnancies in 415 women (Table 1). Eighty-eight
pregnancies were exposed to IFNB (10 to Betaferon, 21
to Rebif 22, 22 to Rebif 44, 35 to Avonex) for a mean
duration of exposure of 4.6 ± 5.8 weeks (range −4 - 41)
and 17 pregnancies were exposed to GA for a mean dur-
ation of exposure of 4.9 ± 2.8 weeks (range 2–12).
We observed 386 full-term deliveries (217 males, 169
females), 75 in exposed to IFNB, 16 in exposed to GA
and 295 in non-exposed subjects. There were eight twin
pregnancies. Epidural analgesia was given to 70 (18.1%)
women. Spontaneous abortions were observed in 28
pregnancies, one (5.9%) in exposed to GA after a
12 weeks of gestation, seven (7.9%) in exposed to IFNB
after a mean of 8.2 ± 1.6 weeks of gestation, and 20
(6.3%) in non-exposed patients, after a mean of 8.5 ±
2.3 weeks. Moreover, we observed two still births (one inFigure 1 Flow-chart of the pregnancies enrolled in the study GA: glatIFNB exposed group and one in non-exposed group),
two extra-uterine pregnancies (both in the non-exposed
group) and five voluntary abortions, all in the IFNB
exposed group.
The risk of spontaneous abortion after GA exposure
was assessed comparing exposed pregnancies (#17) with
pregnancies occurring in patients previously treated with
GA or never treated with other DMDs (#202), excluding
patients who had received IFNBs (Table 1). Patients
exposed to GA did not differ from patients non-exposed
in terms of demographic and clinic characteristics, with
the exception of EDSS score that was significantly higher
in patients exposed to GA (Table 1).
In the multivariate analysis, spontaneous abortion was
related only with higher age at conception and previous
pregnancies (Table 2). GA exposure did not increase the
risk of spontaneous abortion (OR = 0.44; 95% CI 0.04-
4.51; p = 0.492).Preterm and caesarean delivery
Mean gestational age was 38.6 ± 2.6 weeks in pregnan-
cies exposed to GA, 37.8 ± 2.1 in those exposed to IFNB,
and 38.5 ± 2.4 in those non epxosed. Gestational age was
significantly lower after exposure to IFNB than in non
exposed (p = 0.048). There was no difference between
pregancies exposed to GA and either those exposed to
IFNB or non exposed (p > 0.735).
Preterm delivery was observed in 4 subjects exposed
to GA (25% of full term deliveries), 25 exposed to IFNB
(32.8% of full term deliveries), and 58 in non exposed
(20.1% of full term deliveries).
Caesarean delivery was observed in 7 subjects exposed
to GA (43.8% of full term deliveries), 34 exposed to
IFNB (44.7% of full term deliveries), and 130 non
exposed (45.1% of full term deliveries).iramer acetate IFNB: Interferon-β.
Table 1 Characteristics of the study sample
Exposed to
GA * (#17)
Non exposed to
GA (# 202)
p
Age at conception, mean
(SD) years
31.8 (3.7) 31.8 (5.1) 0.987
Education, mean
(SD) years
13.3 (3.8) 13.2 (3.6) 0.937
Disease duration, mean
(SD) years
8.3 (4.6) 6.8 (5.5) 0.308
EDSS at conception, mean
(SD)
2.0 (1.4) 1.3 (0.8) 0.002
Previous abortion (#,%) 1 (5.9) 18 (8.9) 0.670
Previous pregnancy (#,%) 3 (17.6) 33 (16.4) 0.845
Smoking during pregnancy
(#,%)
2 (11.8) 15 (7.5) 0.525
*Mean duration of exposure: 4.9 ± 2.8 weeks.
GA: Glatiramer Acetate; SD: Standard Deviations; EDSS: Expanded Disability
Status Scale.
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who had received IFNBs were excluded. In the multivari-
ate analysis, caesarean delivery was related only to pre-
term delivery, whereas lower gestational age and lower
education were associated with caesarean delivery
(Table 2).
Birth weight and length
Mean birthweight was 3357 ± 616 gr in pregnancies
exposed to GA, 3010 ± 513 gr in those exposed to IFNB,
and 3209 ± 488 in those non exposed. Mean birthweight
was significantly lower after exposure to IFNB than in
other two groups (p < 0.036). There was no difference
between pregancies exposed to GA and those non
exposed (p = 0.751).
Mean birthlength was 50.1 ± 3.1 cm in pregnancies
exposed to GA, 48.7 ± 3.4 in those exposed to IFNB, and
49.9 ± 3.2 in those non exposed. Mean birth length wasTable 2 Significant predictors of spontaneous abortion,
preterm delivery, caesarean delivery
OR 95% CI p
Spontaneous abortion*
Higher age at conception 1.23 1.04 - 1.46 0.018
Previous pregnancies 3.12 1.01 - 9.69 0.048
Preterm delivery*
Caesarean delivery 0.22 0.10 – 0.49 < 0.001
Caesarean delivery*
Gestational age 0.72 0.62 – 0.85 < 0.001
Education 0.90 0.81 – 0.98 0.022
* Other possible predictors included in the models (age at conception,
educational level, disease duration, Expanded Disability Status Scale, previous
pregnancies and abortions, smoking, alcohol glucocorticoid and substance
exposure during pregnancy, gestational age, caesarean delivery, gender of the
baby) were not significantly associated with the dependent variable (p > 0.11).
OR: Odd Ratio; CI: Confidence Interval.significantly lower after exposure to IFNB than in non
exposed (p = 0.014). There was no difference between
pregancies exposed to GA and either those exposed to
IFNB or non exposed (p > 0.360).
In the multivariate analysis (excluding patients who
had received IFNBs), an older age at disease onset, pre-
term and caesarean delivery were related to a lower
weight, whereas only preterm delivery was associated to
a lower length of the babies (Table 3).
Pregnancy complications and follow-up of the babies
Maternal complications occurred in 4 out of 16 (25%)
full term deliveries in the GA exposed pregnancies and
in 28 out of 190 (15%) in the non exposed group
(Table 4). The most frequent complication was threa-
tened abortion in the non-exposed group. In exposed
women we observed one case of placental abnormality,
one case of eclampsia, one case of cholestasis and one
case of headache. No fetal complication was observed
in pregnancies exposed to GA. In the non exposed
group, the most frequent fetal complication was minor
respiratory distress, not requiring intensive care
(Table 4). Finally, in a median follow-up period of
2.1 years, we observed two developmental abnormalities
(mild speech disorders), both in the non exposed
group.
Discussion
To date the information on pregnancy and fetal out-
comes after in-utero exposure to GA in patients with
MS is limited. The main data on the safety of GA is
from the manufacturer’s post-marketing surveillance,
that suggests no increased risk in terms of spontaneous
abortion and other outcomes. Indeed the reported mis-
carriage rate (17%) is similar to that observed in the gen-
eral population [7].
With regard the experience of Italian centers routine
practice was to discontinue DMDs before a pregnancy
program and to advise preventing pregnancy while on
therapy. However, in a previous multicentric, prospectiveTable 3 Significant predictors of birth weight and length
Beta p
Birthweight*
Older age at disease onset −0.188 0.012
Preterm delivery −0.331 < 0.001
Caesarean delivery −0.233 0.003
Birthlength*
Preterm delivery −0.307 < 0.001
* Other possible predictors included in the models (age at conception,
educational level, disease duration, Expanded Disability Status Scale, previous
pregnancies and abortions, smoking, alcohol glucocorticoid and substance
exposure during pregnancy, gestational age, caesarean delivery, gender of the
baby) were not significantly associated with the dependent variable (p > 0.12).
Table 4 Maternal and fetal complications in exposed and
non-exposed pregnancies
GA-Exposed
pregnancies (#16)
Non-exposed
pregnancies (#190)
Maternal
complications
1 placental detachment 8 threatened abortion
1 pre-eclampsia/eclampsia 4 placentar abnormalities
1 headache 5 gestational diabetes
1 cholestasis at VI month 3 pre-eclampsia/eclampsia
2 kidney colic
2 varicella infection
1 minor infection
1 uterine atony
1 meningism
1 metrorrhagia
Fetal
complications
0 4 respiratory distress
2 jaundice
1 acute fetal distress
1 intrauterine growth
retardation
1 hip dysplasia
1 dehydration
1 anemia requiring
transfusion
1 renal pelvis distension
GA: glatiramer acetate.
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we observed 115 unplanned pregnancies occurred dur-
ing DMD treatment (88 exposed to IFNB, 17 to GA). As
for GA, in the present study we found no significant as-
sociation between drug exposure and increased risk of
spontaneous abortion, after an average exposure of ap-
proximately 4 weeks. Moreover, the risk of spontaneous
abortion was comparable to that of the general
population.
Similar findings were reported by Weber-Schoendorfer
et al., in a prospective observational cohort study [6],
assessing the outcomes of 69 pregnancies exposed to
IFNB and 31 exposed to GA (the latter with a median
duration of exposure of 6.9 weeks).
As for other pregnancy and fetal outcomes, in our
study GA exposure was associated with neither a higher
risk of preterm and caesarean delivery nor a lower
weight and length of the babies. It has to be noted that
lower birth-weight and –lenght resulted to be related
with the exposure to IFNB. This difference was observed
also by Weber-Schoendorfer and co-workers. This result
may be due, at least in part, by the different mechanism
of action of the drugs. Although IFNBs are macromole-
cules that do not easily pass the placenta, it is knownthat cytokine imbalance may affect pregnancy outcomes
[13-15].
Furthermore no fetal complication was observed in
pregnancies exposed to GA and , in a median follow-up
period of 2.1 years, we did not observe developmental
abnormalities in the GA exposed group. Probably a low
risk of GA teratogenicity may be due to its mechanism
of action [16].
In interpreting the study results, a few possible limita-
tions should be taken into account. The sample size of
GA-exposed pregnancies is small. Moreover, we cannot
exclude the occurrence of recall bias, even if women
were prospectively followed up and the interview was
performed soon after the delivery.
Our study focused on the effects of GA after an aver-
age exposure of approximately 4 weeks, and the conse-
quences of longer duration of exposure cannot be
assessed. However, two smaller uncontrolled studies and
a another recent study performed on a larger population
of patients reported the safety of continuous exposure of
GA for at least eight weeks of gestation [4,9,10]. Neither
drug-related obstetric/neonatal complications nor mal-
formations were observed in the pregnancies exposed to
GA.
Despite these limitations, taken as a whole our find-
ings point to the safety of GA utero exposure in terms
of the risk of spontaneous abortion and the main mater-
nal and fetal outcomes. With respect to what observed
after IFNB exposure, GA exposure did not affect gesta-
tional age, birth-weight and –length, possibly resulting
in a better safety profile. Our study can assist the neur-
ologist facing the issue of pregnancy planning in MS
patients. In particular, in subjects with high disease ac-
tivity and high risk of post-partum relapses, prosecution
of GA treatment may be considered.
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